I appreciate the pain your wishful thinking brings...To...

I appreciate the pain your wishful thinking brings...

To commercialise successfully, all medical products have to solve a problem, and the problem has to cause resonably significant real-world pain (in this case, not physical pain). OSL is developing a solution that targets a known problem, however, solving the problem is simply not enough.

In order to displace current practice, the solution has to be a significant improvement on whatever's being done/used currently (which may be nothing). If the solution is incremental, it won't move the needle. Same if its (relatively) expensive, hard to use or clinically dodgy/whacky. On top of that, the user must have faith in the solution's robust and rigorous scientific, clinical and real world evidence as well as faith in manufacturing (quality) and supply (security). Thats a lot for any cash strapped, early stage company to deliver from the arse end of the planet.

OSL (and any other Aussie biotech) will need to demonstrate to any 3rd party acquirer either massive, derisked potential to massively change clinical practice and/or a robust commercial business case -ie. sustained and increasing sales/revenue. The clinical awesomeness of OncoSil is demonstrably not there, and handsful of sales in Turkey, Greece, Spain etc is simply not a demonstrated commercial business case.

Therefore, OSL mulls only 2 options - continue to tap investors for $ to fuel their exceedingly torturous commercialisation journey or a white knight who will make the problem go away. Either way, current shareholders are f***ed.